CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1), the next medical revolution against cancer

Q3 Medicine

Vacunas Pub Date : 2023-10-01 DOI:10.1016/j.vacun.2023.01.006

Ali Adel Dawood

{"title":"CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1), the next medical revolution against cancer","authors":"Ali Adel Dawood","doi":"10.1016/j.vacun.2023.01.006","DOIUrl":null,"url":null,"abstract":"<div>Despite advances in modern treatment, many cancers have evolved to bypass the immune system. The immune system either cannot perceive the tumor as foreign or the immune response is hindered. Oncolytic viruses are designed to infect and kill cancer cells. A huge variety of oncolytic viruses have been produced and tested over the last 30 years. The presence of 9 different virus strains in the cells (mouse) at the same time allowed the genes from the different strains to be rearranged via homologous recombination to generate unique chimeric daughter viruses. CHECKvacc is a genetically engineered oncolytic virus (CF33) that is equipped with the human sodium iodide symporter (hNIS) and an anti-PD-L1 antibody. The novel modified viruses will be examined as a monotherapy or in combination with pembrolizumab to determine the safety and efficacy of the treatment regimens. The first patient was dosed in a phase 1 clinical trial to assess the treatment's safety in people with advanced solid tumors. The medicine will be administered either directly into the tumors or intravenously.</div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988723000080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Despite advances in modern treatment, many cancers have evolved to bypass the immune system. The immune system either cannot perceive the tumor as foreign or the immune response is hindered. Oncolytic viruses are designed to infect and kill cancer cells. A huge variety of oncolytic viruses have been produced and tested over the last 30 years. The presence of 9 different virus strains in the cells (mouse) at the same time allowed the genes from the different strains to be rearranged via homologous recombination to generate unique chimeric daughter viruses. CHECKvacc is a genetically engineered oncolytic virus (CF33) that is equipped with the human sodium iodide symporter (hNIS) and an anti-PD-L1 antibody. The novel modified viruses will be examined as a monotherapy or in combination with pembrolizumab to determine the safety and efficacy of the treatment regimens. The first patient was dosed in a phase 1 clinical trial to assess the treatment's safety in people with advanced solid tumors. The medicine will be administered either directly into the tumors or intravenously.

查看原文本刊更多论文

CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1)，抗癌的下一个医学革命

尽管现代治疗取得了进步，但许多癌症已经进化到绕过免疫系统。免疫系统要么不能将肿瘤视为外来物，要么免疫反应受阻。溶瘤病毒被设计用来感染和杀死癌细胞。在过去的30 年里，各种各样的溶瘤病毒被制造出来并进行了测试。在细胞(小鼠)中同时存在9种不同的病毒株，使得来自不同病毒株的基因通过同源重组重新排列，产生独特的嵌合子病毒。CHECKvacc是一种基因工程溶瘤病毒(CF33)，配备了人类碘化钠同调体(hNIS)和抗pd - l1抗体。新的修饰病毒将作为单一疗法或与派姆单抗联合治疗进行检查，以确定治疗方案的安全性和有效性。第一名患者正在进行一期临床试验，以评估该疗法对晚期实体瘤患者的安全性。药物可以直接注射到肿瘤中，也可以静脉注射。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vacunas Medicine-Infectious Diseases

CiteScore

3.90

自引率

0.00%

发文量

138

审稿时长

62 days

期刊介绍： Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.